VANTAGE

Aligning Capital and Science for Patients

The faster, smarter platform for valuation and decision making

Built on 30 years of research from MIT's Andrew Lo and industry leaders.

The Challenge

Four Key Pain Points

Standardizing valuations, tracking portfolio growth between transactions, and anticipating capital needs across dozens of uncertain programs.

How can I show growth in my portfolio value without a transaction?

How do I value significant technological breakthroughs in discovery-stage companies?
What is the cadence of value inflecting events across my portfolio?

How can I standardize valuation across my portfolio?

How can I ensure my portcos are using defensible assumptions across development stages?
How can I standardize valuation methods for each of my portfolio companies?
How can I improve communication with my portfolio companies?

How do I balance concentration versus diversification?

What is my median outcome across multiple uncertain catalysts?
Where is the next marginal dollar I want to invest?

What key events are coming up for my portcos next year?

Which of my portcos is going to raise capital next year?
When I should I raise my next fund?

The Reality of Drug Development

It's Not a Straight Line

Drug development is a maze of decisions, while traditional tools force you to pretend it's a highway

The Traditional Approach

Linear models miss the complexity

Traditional tools force you to pick one path and model it. But reality has hundreds of paths.

"Just project when you'll hit each milestone"

No room for pivots

Single indication only

Binary success/fail

Ignores optionality

Decision Tree

Decision Point

Success

Partner

Fail/Stop

The Problem

The Spreadsheet Bottleneck

Every "what if" question means building another spreadsheet from scratch

"What if Phase 2 fails but we pivot to Indication B?"

Build another spreadsheet

"What if we partner after Phase 1?"

Build another spreadsheet

"What if we run two indications in parallel?"

Build another spreadsheet

"What if we accelerate into Phase 3?"

Build another spreadsheet

∞

Possible paths

vs.

Spreadsheet at a time

The Solution

VANTAGEA New Approach to Keep Platform Value Visible

Turn platform complexity and scientific programs into a defensible, continuously updated enterprise valuation.

Value Your Full Innovation Potential

Capture the value of your pipeline and your platform: lead programs, indication expansion, technology readthrough, and partnership potential.

Build & Simulate Scenarios

Embrace uncertainty with scenario-based modeling across programs, probabilities, and development paths.

Generate Materials Instantly

Create auditable outputs that answer key strategic questions in board-ready format.

Update Easily as Pipeline Evolves

When programs advance or new assets emerge, update the model in minutes.

Platform companies are discounted through sum-of-the-parts analysis when their technologies create option value.

Built for Rigorous Analysis

Everything You Need to Turn Complex Data into Clear Decisions

Whether you're a biotech VC managing a portfolio or a platform biotech exec making R&D decisions, Vantage provides rigorous quantitative analysis.

rNPV Engine

Risk-adjusted NPV tailored for each program with ML features to produce investor-recognized benchmarks.

Scenario Modeling

Scenario-based modeling across assets, partnerships, and platform expansion with probability weighting.

Sensitivity Analysis

One-click tornado charts showing which assumptions drive value. Identify key risks instantly.

Multi-Asset Waterfall

See how each program contributes to enterprise value, including follow-on assets and platform optionality.

Investor Materials

Auto-generated board and investor materials that connect R&D progress to enterprise value.

Factor Correlations

Quantify the optionality and read through of milestones to other assets in the portfolio.

AI Assistant

Let our LLM build programs and portfolios using QLS benchmarks to bring speed to insight.

Benchmark Database

Benchmark against 1,000+ biotech programs to ground development assumptions in market-accepted data.

The Vantage Approach

Navigate the Full Decision Tree

Build once, explore every path. All your scenarios live in one connected model

Model the Tree

Not Just One Branch

Capture all development paths, indications, and strategic options in a single unified model.

Simulate Outcomes

Probabilistic, Not Deterministic

Monte Carlo simulation across all branches shows the full distribution of outcomes.

Evaluate Decisions

See What Matters

Identify which choices have the biggest impact on value.

What This Means for Your Analysis

Traditional Approach

"What's our NPV?"

$142M

(Average of success and failure outcomes)

Single deterministic number

Limited insight into risk factors

Rebuild for each "what if"

With Vantage

"What's our median outcome?"

$189M (median)

Range: $0 - $340M across 10,000 simulations

Statistical distribution of portfolio value

Probability weighted scenarios

Toggle options instantly

Product Demo

See Vantage in Action

Watch how Vantage transforms complex biotech valuations into clear, defensible insights — in minutes, not weeks

Case Study

How a Life Sciences Fund Standardized Valuation Across 18 Portfolio Companies

The Challenge

With an LP meeting six weeks away, each portfolio company used different valuation methods, assumptions, and reporting formats. Partners were spending weeks manually normalizing financials across 18 companies.

The Approach

Deployed Vantage across the portfolio in 30 days. Established a standardized valuation framework. Preserved company-specific assumptions within a consistent methodology. Created a unified, portfolio-level dashboard. Enabled real-time visibility across assets and stages.

The Outcome

LP review preparation was reduced from weeks to days. Reports were standardized, assumptions aligned, and follow-on financing conversations accelerated with clean, normalized data.

Portfolio Co Standardized in 30 Days

30 Days

Full Portfolio Rollout

Weeks → Days

LP Prep Time

Companies Standardized

Unified Dashboard

The Team

Financial Innovation from MIT and Industry Leaders

Cambridge, MA-based. Built with MIT professors, Nobel Laureates, and industry thought leaders. Based on over 30 years of research from MIT's Andrew Lo.